|X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization|
RL Camp, M Dolled-Filhart, DL Rimm
Clinical cancer research 10 (21), 7252-7259, 2004
|The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014|
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
|Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma|
LA Garraway, HR Widlund, MA Rubin, G Getz, AJ Berger, S Ramaswamy, ...
Nature 436 (7047), 117-122, 2005
|Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features|
CJ Creighton, X Li, M Landis, JM Dixon, VM Neumeister, A Sjolund, ...
Proceedings of the National Academy of Sciences 106 (33), 13820-13825, 2009
|Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin|
KL Cepek, SK Shaw, CM Parker, GJ Russell, JS Morrow, DL Rimm, ...
Nature 372 (6502), 190-193, 1994
|Validation of tissue microarray technology in breast carcinoma|
RL Camp, LA Charette, DL Rimm
Laboratory investigation 80 (12), 1943-1949, 2000
|Alpha 1 (E)-catenin is an actin-binding and-bundling protein mediating the attachment of F-actin to the membrane adhesion complex.|
DL Rimm, ER Koslov, P Kebriaei, CD Cianci, JS Morrow
Proceedings of the National Academy of Sciences 92 (19), 8813-8817, 1995
|Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis|
PM Weinberger, Z Yu, BG Haffty, D Kowalski, M Harigopal, J Brandsma, ...
Journal of clinical oncology 24 (5), 736-747, 2006
|Automated subcellular localization and quantification of protein expression in tissue microarrays|
RL Camp, GG Chung, DL Rimm
Nature medicine 8 (11), 1323-1328, 2002
|Programmed death ligand-1 expression in non-small cell lung cancer|
V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ...
Laboratory investigation 94 (1), 107-116, 2014
|Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer|
J McLaughlin, G Han, KA Schalper, D Carvajal-Hausdorf, V Pelekanou, ...
JAMA oncology 2 (1), 46-54, 2016
J Bordeaux, AW Welsh, S Agarwal, E Killiam, MT Baquero, JA Hanna, ...
Biotechniques 48 (3), 197-209, 2010
|A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer|
DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ...
JAMA oncology 3 (8), 1051-1058, 2017
|Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas|
K Hoek, DL Rimm, KR Williams, H Zhao, S Ariyan, A Lin, HM Kluger, ...
Cancer research 64 (15), 5270-5282, 2004
|Differences in risk factors for breast cancer molecular subtypes in a population-based study|
XR Yang, ME Sherman, DL Rimm, J Lissowska, LA Brinton, B Peplonska, ...
Cancer Epidemiology Biomarkers & Prevention 16 (3), 439-443, 2007
|In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast CarcinomasPD-L1 mRNA Positivity and Outcome in Breast Cancer|
KA Schalper, V Velcheti, D Carvajal, H Wimberly, J Brown, L Pusztai, ...
Clinical Cancer Research 20 (10), 2773-2782, 2014
|Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology|
K Bera, KA Schalper, DL Rimm, V Velcheti, A Madabhushi
Nature reviews Clinical oncology 16 (11), 703-715, 2019
|Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma|
G Garcia-Rostan, G Tallini, A Herrero, TG D’Aquila, ML Carcangiu, ...
Cancer research 59 (8), 1811-1815, 1999
|Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …|
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311, 2017
|RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune …|
S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ...
Clinical Cancer Research 22 (6), 1499-1509, 2016